Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 1;57(40):13101-13105.
doi: 10.1002/anie.201806854. Epub 2018 Sep 4.

Colorimetric Carbonyl Sulfide (COS)/Hydrogen Sulfide (H2 S) Donation from γ-Ketothiocarbamate Donor Motifs

Affiliations

Colorimetric Carbonyl Sulfide (COS)/Hydrogen Sulfide (H2 S) Donation from γ-Ketothiocarbamate Donor Motifs

Yu Zhao et al. Angew Chem Int Ed Engl. .

Abstract

Hydrogen sulfide (H2 S) is a biologically active molecule that exhibits protective effects in a variety of physiological and pathological processes. Although several H2 S-related biological effects have been discovered by using H2 S donors, knowing how much H2 S has been released from donors under different conditions remains challenging. Now, a series of γ-ketothiocarbamate (γ-KetoTCM) compounds that provide the first examples of colorimetric H2 S donors and enable direct quantification of H2 S release, were reported. These compounds are activated through a pH-dependent deprotonation/β-elimination sequence to release carbonyl sulfide (COS), which is quickly converted into H2 S by carbonic anhydrase. The p-nitroaniline released upon donor activation provides an optical readout that correlates directly to COS/H2 S release, thus enabling colorimetric measurement of H2 S donation.

Keywords: anti-inflammation; carbonyl sulfide; colorimetry; hydrogen sulfide; γ-ketothiocarbamate.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(a) Time-dependent UV-Vis spectra of γ-KetoTCM-1 and PNA. (10 mM PBS, pH 7.4, 25 μg CA/mL, 37 ºC). Inset: color of the solution at t = 0 (left) and t = 24 h (right). (b) Time-dependent absorbance of γ-KetoTCM-1 (333 nm) and PNA (381 nm) (10 mM PBS, pH 7.4). (c) pH dependence of PNA formation from of γ-KetoTCM-1 in PBS at pH 8.0 (blue), pH 7.4 (red), and pH 6.0 (black) at 37 ºC. (d) PNA formation (red) and H2S release (blue) upon γ-KetoTCM-1 (50 μM) activation in PBS (pH 7.4, 10 mM) containing BSA (5 mg/mL) at 37 ºC. Inset: Correlation between measured [H2S] and PNA formation. AP: PNA absorbance (381 nm); AD: γ-KetoTCM-1 absorbance (333 nm). Experiments were performed in triplicate. Results are expressed as mean ± SD (n=3).
Figure 2.
Figure 2.
Measurement of PNA formation after compound activation. AP: PNA absorbance (381 nm); AD: compound absorbance (at λmax). Experiments were performed in triplicate. Results are expressed as mean ± SD (n = 3)
Figure 3.
Figure 3.
PNA formation after incubating γ-KetoTCM-1 (50 μM) in PBS (pH 7.4, 10 mM) only (1), or PBS containing 250 μM of Cys (2), NAC (3), Hcy (4), GSH (1.0 mM, 5), Lys (6), Ser (7), Gly (8), or GSSG (9) for 4 h at 37 ºC. Experiments were performed in triplicate. Results are expressed as mean ± SD (n = 3).
Figure 4.
Figure 4.
H2S Delivery from γ-KetoTCM-1 in HeLa cells. HeLa cells were treated with SF7-AM (5 μM) for 30 min, washed, and incubated with FBS-free DMEM only (left), with 100 μM γ-KetoCM-1 (middle), or with γ-KetoTCM-1 (right) for 2 h. Cells were then washed and imaged in PBS. Scale bar: 100 μm.
Figure 5.
Figure 5.
Effects of γ-KetoTCM-1 on LPS-induced NO2 formation. RAW 264.7 cells were pretreated with γ-KetoTCM-1 (25 μM) or control compounds for 6 h, followed by LPS (1.0 μg/mL, 18-h). Results are expressed as mean ± SD (n = 4). ***P < 0.001 vs the control group; ###P < 0.001 vs vehicle-treated group; and $$$P < 0.001 between γ-KetoTCM-1-treated and γ-KetoCM-1-treated groups.
Scheme 1.
Scheme 1.
(a) Previous design of COS-based H2S donors; (b) colorimetric COS-based H2S donors and proposed COS/H2S releasing pathway; (c) control compound activation; (d) activation of CO2-releasing control compounds; (e) synthesis of γ-KetoTCM-based COS/H2S donors and control compounds.

Similar articles

Cited by

References

    1. Abe K, Kimura H, J. Neurosci. 1996, 16, 1066–1071. - PMC - PubMed
    1. Wang R, Physiol. Rev. 2012, 92, 791–896; - PubMed
    2. Szabo C, Nat. Rev. Drug. Discov. 2007, 6, 917–935. - PubMed
    1. Fukuto JM, Carrington SJ, Tantillo DJ, Harrison JG, Ignarro LJ, Freeman BA, Chen A, Wink DA, Chem. Res. Toxicol. 2012, 25, 769–793; - PMC - PubMed
    2. Kabil O, Banerjee R, Antioxid. Redox. Signal. 2014, 20, 770–782. - PMC - PubMed
    1. Li L, Rose P, Moore PK, Annu. Rev. Pharmacol. Toxicol. 2011, 51, 169–187; - PubMed
    2. Olson KR, Antioxid. Redox. Signal. 2012, 17, 32–44; - PMC - PubMed
    3. Szabo C, Antioxid. Redox. Signal. 2012, 17, 68–80. - PMC - PubMed
    1. Pluth MD, Bailey TS, Hammers MD, Hartle MD, Henthorn HA, Steiger AK, Synlett 2015, 26, 2633–2643;
    2. Zhao Y, Biggs TD, Xian M, Chem. Commun. 2014, 50, 11788–11805; - PMC - PubMed
    3. Zhao Y, Pacheco A, Xian M, Handb. Exp. Pharmacol. 2015, 230, 365–388; - PubMed
    4. Zheng Y, Yu B, De La Cruz LK, Roy Choudhury M, Anifowose A, Wang B, Med. Res. Rev. 2018, 38, 57–100; - PubMed
    5. Szabo C, Papapetropoulos A, Pharmacol. Rev. 2017, 69, 497–564. - PMC - PubMed

Publication types